Zai Lab Limited

ZLAB

US98887Q1040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
26.05 ^USD	+2.64%		+2.96%	-0.53%

Jan. 17	Sector Update: Health Care Stocks Decline Late Afternoon	MT
Jan. 17	Sector Update: Health Care Stocks Softer Friday Afternoon	MT

Zai Lab, Pfizer Collaborate for Marketing Antibacterial Drug in China

November 21, 2024 at 05:11 am EST

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Zai Lab Limited

Sector Update: Health Care Stocks Decline Late Afternoon	Jan. 17	MT
Sector Update: Health Care Stocks Softer Friday Afternoon	Jan. 17	MT
Zai Lab's Schizophrenia Drug Application Accepted by Chinese Regulator; Shares Rise	Jan. 17	MT
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia	Jan. 17	CI
Zai Lab Reports Improved Overall Survival in Phase 3 Trial of Tivdak in Cervical Cancer Patients	Jan. 15	MT
Zai Lab Limited Announces Positive Topline Results for Tivdak in the China Subpopulation of the Global Phase 3 Innovatv301 Trial in Patients with Recurrent or Metastatic Cervical Cancer	Jan. 15	CI
Zai Lab Limited Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 01:30 PM	Jan. 14
Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading	Jan. 10	MT
Vertex, Zai Lab Partner Over Povetacicept Development in China, 4 Other Regions	Jan. 10	MT
Vertex Pharmaceuticals Incorporated and Zai Lab Limited Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore	Jan. 10	CI
Zai Lab Licenses MediLink Therapeutics' Antibody-Drug Conjugate Platform	Jan. 10	MT
Zai Lab Secures 300 Million Yuan Debt Facility	Jan. 05	MT
Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Jan. 02	MT
Zai Lab Limited Announces Resignation of Kai-Xian Chen as Independent Non-Executive Director	Dec. 31	CI
Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading	Dec. 04	MT
Zai Lab Limited Presents at Citi's 2024 Global Healthcare Conference, Dec-04-2024 09:30 AM	Dec. 04
Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	Dec. 03	MT
NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint	Dec. 02	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Dec. 02	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday Ahead of Week Promising Crucial Economic Data	Dec. 02	MT
Zai Lab, NovoCure Say Pancreatic Cancer Trial Meets Primary Endpoint	Dec. 02	MT
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy for Pancreatic Cancer	Dec. 02	CI
Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List	Nov. 29	MT
Zai Lab Limited Announces the Inclusion of Augtyro (Repotrectinib) for Ros1+ Nsclc and Other Updates in China?S National Reimbursement Drug List	Nov. 27	CI
Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Monday Trading	Nov. 25	MT

Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and Efgartigimod, and others.

Employees

2,175

Sector

Pharmaceuticals

Calendar

2025-03-03 - Q4 2024 Earnings Release (Projected)

More about the company